Highest-materiality recent filing
Glaukos files investor presentation; no material new information
Exhibit 99.1 is an investor presentation dated August 2026; only disclaimer text provided.
Glaukos Q2 net sales $185.6M (+50% YoY); raises FY2026 guidance to $680-700M
Record net sales $185.6M, up 50% YoY; U.S. glaucoma sales $118.5M (+64%).
Glaukos shareholders elect two Class II directors; approve say-on-pay and auditor ratification
Denice M. Torres: 40,843,317 for, 11,169,168 withheld (3,024,243 broker non-votes).
Glaukos files 8-K to announce investor presentation; no material new data
The 8-K states the investor presentation (Exhibit 99.1) will be used in meetings with investors and stakeholders.
Glaukos Q1 record sales $150.6M (+41% YoY); raises FY2026 guidance to $620-635M
Record net sales $150.6M (+41% YoY, +39% constant currency).
Glaukos posts Q4 2021 investor presentation with no material new disclosures
Company made available a March 2026 investor presentation via 8-K Item 7.01.
Glaukos Q4 record sales $143.1M (+36% YoY); reaffirms FY2026 guidance $600-620M
Q4 net sales $143.1M (record), +36% YoY; full year $507.4M, +32% YoY.
Glaukos reports preliminary Q4 2025 net sales ~$143M (+36% YoY); reaffirms FY2026 guidance $600-620M
Q4 2025 net sales ~$143M (+36% YoY); FY2025 net sales ~$507M (+32% YoY).
Glaukos files 8-K furnishing November 2025 investor presentation; no material updates disclosed
Investor presentation dated November 2025 is furnished under Regulation FD and will be used in meetings.
Glaukos Q3 revenue $133.5M (+38% YoY); raises 2025 guide, introduces 2026 outlook
Record net sales $133.5M, up 38% YoY; U.S. Glaucoma sales $80.8M (+57% YoY).
Glaukos posts investor presentation for August 2025; no specific financial updates visible
Investor presentation dated August 2025 made available via SEC filing and company website.
Glaukos Q2 record net sales $124.1M (+30% YoY); raises FY 2025 guidance to $480-486M
Record net sales $124.1M, up 30% YoY; glaucoma sales $103.5M (+36%), U.S. glaucoma $72.3M (+45%).
Glaukos stockholders elect directors, approve say-on-pay, ratify EY at annual meeting
Elected Class I directors Foley, Hoffmeister, and Kliman; broker non-votes of 3,221,029.
Glaukos files routine investor presentation; no material new information disclosed
Filed Form 8-K with an investor presentation dated May 2025.
Glaukos Q1 net sales record $106.7M (+25% YoY); net loss narrows to $0.32/sh from $0.82
Record Q1 net sales $106.7M, up 25% reported and 26% constant currency vs $85.6M last year.
Glaukos posts March 2025 investor presentation; no specific updates disclosed
Investor presentation filed under Item 7.01 Regulation FD; no earnings or guidance included.
Glaukos Q4 record net sales $105.5M, +28% YoY; guides FY2025 $475-485M
Q4 net sales record $105.5M, +28% YoY; glaucoma segment $84.1M (+39%).
Glaukos files January 2025 investor presentation; no specific new data disclosed in excerpt
Filing under Item 7.01 for Regulation FD; presentation to be used in investor meetings.
Glaukos receives $53.2M from capped call unwind on convertible notes
Option counterparties paid $53.2M to Glaukos under Capped Call Unwind Agreements.
Glaukos partially unwinds capped calls on 2027 convertible notes; receives cash based on VWAP
Entered into unwind agreements for 50% of capped call transactions associated with $287.5M 2.75% convertible notes due 2027.
Glaukos files routine investor presentation for November 2024; no specific new data
Company furnished an investor presentation dated November 2024 under Regulation FD.
Glaukos Q3 revenue $96.7M (+24% YoY), raises 2024 guidance to $377-379M
Record Q3 net sales of $96.7M (+24% YoY); glaucoma segment $76.0M (+30%), corneal health $20.6M (+5%).
Glaukos redeems all $57.5M of 2.75% Convertible Notes due 2027; conversion by Dec 13, 2024
Company issued notice to redeem all $57.5M aggregate principal of 2.75% Convertible Senior Notes due 2027.
Glaukos provides investor presentation; no material new facts in filing text
Presentation dated August 2024; full content not available in provided text.
Glaukos files 8-K/A to correct $3.3M debt cost accounting; GAAP EPS overstated by $0.06
Corrected reclassification of $3.3M unamortized debt issuance costs from interest expense to additional paid-in capital for the June 2024 convertible note exchange.
Glaukos reports record Q2 sales $95.7M (+19% YoY), raises FY2024 guidance
Record net sales of $95.7M, up 19% reported / 20% constant currency YoY.
Glaukos exchanges $230M of 2.75% convertible notes for 4.25M shares of common stock
Exchanged $230M principal of 2.75% Convertible Senior Notes due 2027 for 4,253,423 common shares and cash.
Glaukos exchanges $230M of 2.75% Convertible Notes due 2027 for common stock
Glaukos entered agreements to repurchase $230M of its 2.75% Convertible Senior Notes due 2027.
Glaukos stockholders approve amended 2015 omnibus incentive plan; directors elected
Stockholders approved Amended and Restated 2015 Omnibus Incentive Plan, reducing share reserve to 4.7M new shares plus rollover of outstanding awards.
Glaukos furnishes May 2024 investor presentation with no specific financial updates
Company furnished a standard investor presentation as Exhibit 99.1; no new financial results or guidance disclosed.
Record Q1 net sales of $85.6M (+16% YoY); raised 2024 guidance to $357-$365M
Glaucoma segment sales $67.2M (+20% YoY); Corneal Health $18.4M (+4% YoY).
Glaukos makes investor presentation available; no material new facts disclosed
Company posted an investor presentation dated February 2024 on its website.
Glaukos reports record Q4 net sales $82.4M, up 16% YoY; FY2023 sales $314.7M, up 11%
Record Q4 2023 net sales $82.4M, up 16% YoY; glaucoma $60.6M (+15%), corneal health $21.8M (+19%).
Glaukos reports preliminary Q4 2023 net sales >$81M, FY >$313M; reaffirms 2024 guidance $350-360M
Preliminary Q4 2023 net sales exceeded $81 million.
Glaukos receives FDA approval for iDose TR; 2024 revenue guidance $350-$360M
FDA approved iDose TR (travoprost intracameral implant) for reducing IOP in OHT or OAG; launch expected late Q1 2024.
Glaukos Q3 net sales up 10% to $78M; raises FY2023 guidance to $307-310M
Net sales $78.0M (+10% YoY); glaucoma $58.3M (+9%), corneal health $19.7M (+12%).
Glaukos furnishes August 2023 investor presentation; no specific data in exhibit
Presentation filed under Regulation FD; exhibit text only contains a standard disclaimer.
Glaukos Q2 net sales up 11% to $80.4M; raises FY2023 revenue guidance
Q2 net sales $80.4M, +11% YoY; glaucoma sales $61.9M (+10%), corneal health $18.5M (+11% YoY).
Glaukos stockholders elect Torres and Weisner as Class II directors; ratify Ernst & Young as auditor
Two Class II directors elected: Denice M. Torres (29,021,555 for; 11,852,403 withheld) and Aimee S. Weisner (39,492,847 for; 1,381,111 withheld).
Glaukos makes May 2023 investor presentation available; no specific new data in filing
Filed investor presentation dated May 2023 for use in stakeholder meetings.
Glaukos Q1 net sales rise 9% to $73.9M; guides 2023 sales up; GAAP net loss widens to $34.6M
Q1 2023 net sales $73.9M (+9% YoY); glaucoma $56.2M (+9%), corneal health $17.7M (+10%).
Glaukos furnishes March 2023 investor presentation; no material new information disclosed
Company filed an investor presentation under Item 7.01 Regulation FD Disclosure.
Glaukos Q4 net sales $71.2M, down 3% YoY; full-year net loss $99.2M; guides 2023 sales $290-295M
Q4 net sales $71.2M (-3% YoY); glaucoma $52.9M, corneal health $18.3M.
Glaukos furnishes January 2023 investor presentation; no material new information
Presentation filed under Item 7.01 as Exhibit 99.1 on January 10, 2023.
Glaukos amends Bylaws to incorporate universal proxy rules and update advance notice provisions
Amendments adopt SEC Rule 14a-19 universal proxy requirements into advance notice provisions for director nominations.
Glaukos files November 2022 investor presentation; no material changes disclosed
Routine investor presentation furnished under Item 7.01, not filed.
Glaukos Q3 net loss $27.6M ($0.58 EPS); revenue down 4.6% YoY to $71.3M; raises 2022 sales outlook
Net sales $71.3M, down 4.6% reported (1.6% constant currency) vs $74.7M in Q3 2021.
Glaukos files investor presentation for September 2022; no specific figures disclosed in excerpt
Company furnished a new investor presentation (Exhibit 99.1) dated September 2022.
Glaukos Q2 net sales $72.7M, down 7% YoY; raises FY2022 guidance to $275-280M
Net sales of $72.7M in Q2 2022, down 7% YoY; glaucoma $56.1M, corneal health $16.6M.
Glaukos shareholders elect three Class I directors at June 2 annual meeting
Mark J. Foley, David F. Hoffmeister, and Gilbert H. Kliman elected as Class I directors with 29.96M, 31.03M, and 30.48M votes for respectively.
Chris M. Calcaterra will step down from his role as the Company’s Chief Operating Officer and will transition to the position of EVP, Global Commercial Operations, effective April 1, 2022.
Joseph E. Gilliam, the Company’s current Chief Financial Officer and Senior Vice President, Corporate Development, has been appointed as the Company’s President and Chief Operating Officer, which appointment will take effect on April 1, 2022.
Alex R. Thurman, the Company’s current Vice President, Finance, has been appointed as the Company’s Senior Vice President, Chief Financial Officer, which appointment will take effect on April 1, 2022.
the independent members of the Board appointed Mark J. Foley, who has served as a member of the Board since 2014 and is the Chair of the Compensation Committee, as the Board’s Lead Independent Director effective December 31, 2021.
the Board, upon the recommendation of the Compensation Committee, appointed Thomas W. Burns, the Company’s President and Chief Executive Officer and a director on the Board since 2002, to serve as the Chairman of the Board of the Company effective upon Dr. Link’s retirement on December 31, 2021.
On December 16, 2021, William J. Link, Ph.D., informed Glaukos Corporation (the “Company”) that he intends to retire from the Company’s Board of Directors (the “Board”) effective December 31, 2021.
Max materiality 0.85 · Median 0.50 · Most common event earnings